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Activation of cytotoxic lymphocytes 
is tightly regulated
NK cells and CD8+ T cells provide de-
fense against virus-infected and trans-
formed cells by releasing perforin and 
granzymes from cytolytic granules and 
by secreting the cytokine interferon 
(IFN)-γ. T cell receptor (TCR) en-
gagement is essential for the activation 
of CD8+ T cells, although costimula-
tory receptors also contribute. NK cell 
activation can be triggered by the liga-
tion of various activating receptors, 
each of which recognizes a diff  erent cell 
surface molecule on the target cell (2). 
The activation threshold of these cyto-
lytic cells is set by the integration of 
  inhibitory signals that counteract the 
activation signals (2). Inhibitory recep-
tors recognize molecules that are ex-
pressed on normal cells as a means of 
protecting healthy cells from attack by 
NK and CD8+ T cells. The prototypic 
inhibitory receptors recognize MHC 
class I molecules and include members 
of the Ly49 and PIR receptor families 
in mice, and the KIR and LILR recep-
tor families in humans (2). These 
  receptors contain tyrosine-based inhibi-
tory motifs (ITIMs) in their intracellular 
domains, which recruit the protein ty-
rosine phosphatases SHP1 and SHP2. 
SHP1 and SHP2 dephosphorylate (and 
thus deactivate) critical signaling mole-
cules, thereby blocking the activation 
of eff   ector functions. NK cells and 
CD8+ T cells also express other inhibi-
tory receptors, including CEACAM1, 
LAIR1, and KLRG1, whose ligands are 
now being characterized. In this issue, 
Ito et al. (p. 289) identify the cell ad-
hesion molecule E-cadherin as the li-
gand that engages KLRG1 in mice and 
men (3).
KLRG1 inhibits effector cell responses
KLRG1 is a transmembrane receptor 
belonging to the lectin-like superfam-
ily, which mediates inhibition via a 
  cytoplasmic ITIM motif. KLRG1 is 
preferentially expressed on cells that 
provide rapid eff  ector functions in pe-
ripheral tissues, including subsets of 
NK cells and eff  ector–memory CD8+ 
T cells (4–9). Because these T cells have 
experienced their cognate antigen and 
acquired eff  ector functions in the past, 
they secrete perforin, granzymes, and 
IFN-γ more promptly upon reexposure 
to that antigen. KLRG1 is rapidly up-
regulated on NK cells and CD8+ and 
CD4+ T cells in mice during infection 
with murine cytomegalovirus and Tox-
oplasma gondii, and in humans, during 
chronic infection with human cyto-
megalovirus, Epstein-Barr virus, and 
human immunodefi  ciency virus 1 (5, 6, 
10–13). KLRG1 is also expressed on rat 
mast cells (4, 14).
The inhibitory function of KLRG1, 
its predominant expression on eff  ector 
cells, and its inducible expression dur-
ing infections, collectively suggest that 
KLRG1 might raise the activation thresh-
old of NK and T cells, thereby down-reg-
ulating eff  ector responses in the periphery 
and preventing immunopathology.
KLRG1 binds to cadherins 
on epithelial cells
Until now, the KLRG1 ligand was un-
known. Using a recombinant KLRG1 
tetramer, which is capable of detecting 
the ligand on epithelial cell lines, and 
expression cloning, Ito et al. now iden-
tify E-cadherin as the KLRG1 ligand 
(3). A similar fi  nding was independently 
reported by Gründemann et al. (15). 
Cadherins comprise a family of trans-
membrane glycoproteins that   mediate 
Ca2+-dependent cell–cell adhesion (16). 
They contribute to tissue morphogene-
sis during embryonic development and 
to the maintenance of tissue type and 
architecture. The extracellular region of 
cadherins contains tandem repeats that 
mediate Ca2+-dependent homotypic in-
teractions, and the cytoplasmic domain 
links them to the actin cytoskeleton 
by binding to β-catenin. β-catenin re-
cruits α-catenin, which in turn binds 
directly to actin and to several actin-
binding proteins, including α-actinin, 
vinculin, and formin. This cadherin–
catenin–actin complex is essential for 
the formation and maintenance of the 
cell–cell adhesion complex known as 
the adherens junction. The cadherin 
family includes type I cadherins (epi-
thelial [E]-, neuronal [N]-, placental 
[P], retinal [R]-, and muscle [M]-cad-
herins) and type II cadherins (vascular 
endothelial [VE]-cadherin). E-cadherin 
is found at epithelial cell junctions and 
on Langerhans cells (LCs), a unique 
population of dendritic cells (DCs) 
found in the epidermis. Other cadher-
ins are found in similar structures in 
other cell types. According to Ito et al., 
three of the type I cadherins—E-, N-, 
and R-cadherins—are recognized by 
KLRG1 (3).
What is the signifi  cance of KLRG1–
cadherin interactions? Ito et al. show 
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provide an essential defense against intracellular pathogens and tumors. 
During target cell recognition, these cells receive both activating and inhibi-
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that this interaction triggers an inhibi-
tory pathway that down-regulates NK 
cell cytotoxicity (3). The study by 
Gründemann et al. found that KLRG1–
cadherin interactions predominantly 
  inhibited the expansion of CD8+ T cells 
and their acquisition of eff  ector func-
tions, but had little eff  ect on NK cell 
cytotoxicity. This inhibitory eff  ect oc-
curred when CD8+ T cells were primed 
by nonprofessional antigen-presenting 
cells (15). Collectively, these studies 
demonstrate a role for E-cadherin in 
inhibition of both NK cells and T cells. 
This may have important implications 
for tumor immunosurveillance by NK 
and T cells. For example, E-cadherin 
expression is frequently down-regu-
lated in certain breast cancers, because 
of the loss of one allele of the E-cad-
herin gene CDH1 in combination with 
mutation or epigenetic silencing of the 
remaining allele (17). Cancer cells lack-
ing E-cadherin lose contact   inhibition 
and cell polarity, proliferate more rap-
idly, and acquire an invasive phenotype, 
suggesting that the loss of E-cadherin 
favors tumor growth. However, when 
NK cells and T cells encounter tumor 
cells that lack E-cadherin expression, 
KRLG1 is not engaged. In the absence 
of KLRG1-mediated inhibitory signals, 
the activation threshold of the cells is 
likely to be lower, causing the cells to 
release cytotoxic granules and IFN-γ to 
more readily and rapidly eliminate the 
tumor cells.
In contrast, some tumors may para-
doxically exploit KLRG1–cadherin 
interactions to their advantage. One ex-
ample is aggressive breast tumors, some 
of which initially down-regulate E-cad-
herin to gain motility and metastatic 
potential, but then reexpress the pro-
tein to promote the attachment of me-
tastases and to avoid immune attack 
(17). In addition, epithelial tumors can 
switch from expressing E-cadherin to 
expressing N-cadherin (or other cad-
herins). N-cadherin endows the tumor 
with more motility and invasiveness 
through interactions with ligands on 
endothelial cells and stromal cells (17). 
In both cases, tumors escape immuno-
surveillance by engaging the KLRG1 
inhibitory pathway.
Potential cross-talk between KLRG1 
and 𝗂E𝗃7 integrin
In addition to KLRG1, lymphocytes 
express another receptor for E-cadherin, 
the integrin αEβ7 (CD103) (18). This 
integrin is predominantly expressed on 
lamina propria T cells and intraepithe-
lial lymphocytes (19). Consistent with 
this expression pattern, αEβ7 integrins 
mediate T cell homing and adhesion 
to intestinal epithelial cells via inter-
actions with E-cadherin (19). These 
gut-associated T cells provide immuno-
surveillance against infected, damaged, 
or transformed epithelial cells, and 
participate in tissue repair by secreting 
wound-healing cytokines. Although 
KLRG1 is not expressed on intraepi-
thelial lymphocytes (6), it might be up-
regulated on some αEβ7
+ T cells upon 
infection. NK cell subsets express αEβ7 
and might coexpress KLRG1 during 
steady-state or activation. Although not 
yet tested, coengagement of KLRG1 
and αEβ7 by E-cadherin on NK cells 
and T cells might modulate αEβ7 func-
tion. It has been shown that αEβ7 integ-
rin is regulated by inside-outside signals, 
as αEβ7-expressing cells bind more av-
idly to E-cadherin after the cells are ac-
tivated with phorbol myristate acetate 
or anti-CD3 (19). It is thus possible that 
KLRG1 might transduce signals that 
inhibit αEβ7 integrin activation, thereby 
reducing its avidity for E-cadherin and 
its ability to control lymphocyte migra-
tion and function. The potential im-
pact of KLRG1–cadherin interactions 
on mucosal immunity is an attractive 
theme for future investigations.
KLRG1–cadherin inhibitory 
interactions: the tip of the iceberg?
The interaction between KLRG1 and 
cadherins is remarkably similar to other 
inhibitory interactions between lym-
phocytes and epithelial cells. Indeed, 
activated NK cells and T cells recognize 
another group of cell adhesion mole-
cules, known as human carcinoembry-
onic antigen (CEA)–related adhesion 
molecules (CEACAMs). Recognition 
is mediated by CEACAM1, an inhibi-
tory member of the CEACAM fam-
ily that is expressed on activated NK 
cells, T cells, and other leukocytes. 
CEACAM1 can bind several members 
of the CEACAM family expressed on 
epithelial cells, including CEACAM1 
itself, and these interactions inhibit 
NK cell cytotoxicity against epithelial 
cells (20). Like E-cadherin, the ex-
pression of high levels of CEACAM1 
on some tumor cells increases their 
motility and invasiveness (21). How-
ever, CEACAM1 expression on tumor 
cells may also promote tumorigenesis 
by triggering the CEACAM1 inhibi-
tory pathway on NK and T cells, thus 
blocking their ability to recognize and 
eliminate tumor cells. As lymphocytes 
express multiple orphan inhibitory re-
ceptors, it is possible that additional 
MHC class I–independent inhibitory 
pathways will be identifi  ed,  which 
might help explain the aggressiveness 
of certain epithelial tumors.
The complexity of cytotoxic 
lymphocyte–epithelial cell interplay
The overall picture of cytotoxic lym-
phocyte–epithelial cell interactions is 
becoming increasingly complicated in 
view of the recent demonstration that 
NK cells and T cells can bind cell adhe-
sion molecules through both inhibitory 
and activating receptors. NK cells and 
T cells have been shown to recognize 
adhesion molecules known as nectins 
and nectin-like proteins (necls). Nectins 
and necls, like cadherins, mediate cell–
cell adhesion through homotypic and 
heterotypic interactions (22). These 
proteins form adherens junctions in ep-
ithelial tissues and are linked to the ac-
tin cytoskeleton through actin-binding 
proteins such as afadin, DAL-1/4.1B, 
and human discs large (hDLG) protein 
(22, 23). NK cells and T cells express 
the receptor CD226, which recognizes 
necl-5 and nectin-2, and the receptor 
CD96, which recognizes necl-5 (24–
26). In addition, activated NK cells 
and T cells up-regulate the receptor 
CRTAM, which binds to necl-2 (27). 
Unlike KLRG1, however, the recep-
tors specifi  c for the nectins and necls 
trigger NK cell and T cell activation, 
either alone or in association with the 
β2 integrin LFA-1 (28).
The role of these activating receptor 
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Figure 1.  Lymphocytes express multiple receptors that recognize adhesion, which contrib-
ute to normal epithelial tissue architecture. (A) E-cadherin and nectins/necls form adherens 
junctions (AJ) in healthy epithelial tissues. These receptors, as well as CEACAM1, mediate cell–cell 
interactions via homotypic and/or heterotypic interactions. (B) Loss of cell polarity and tissue archi-
tecture (resulting, for example, from the growth of tumor cells) might favor lymphocyte–epithelial 
cell interactions over epithelial–epithelial interactions. KLRG1 and the integrin αEβ7 on NK and T cells 
bind to E-cadherin (and possibly N- and R-cadherins) on epithelial cells. CEACAM1 mediates homo-
typic adhesion between lymphocytes and epithelial cells. Both KLRG1 and CEACAM1 contain a cyto-
plasmic ITIM and deliver inhibitory signals. CRTAM binds necl-2, whereas CD226 and CD96 bind 
necl-5. CRTAM, CD226, and CD96 transduce positive signals that trigger cytotoxicity and IFN-γ 
  release by NK and T cells.
immunosurveillance is not completely 
understood. Initial studies indicated that 
lymphocyte recognition of the nectins 
and necls provides costimulatory signals 
that trigger NK cell cytotoxicity, as well 
as T cell proliferation and IFN-γ secre-
tion. Thus, we speculate that nectins 
and necls are not easily accessible to the 
immune system in normal tissues, either 
because these molecules are hidden in 
interepithelial junctions or are already 
engaged in homotypic interactions that 
preclude epithelial–lymphocyte interac-
tions (Fig. 1). However, upon neoplas-
tic disruption of tissue organization, 
nectin and necls may become accessible 
to NK and T cells for recognition (Fig. 
1). If this is the case, tumors should 
  decrease their expression of nectins 
and necls to escape immunosurveillance. 
Consistent with this model, many 
  epithelial tumors—particularly nonsmall 
cell lung carcinomas—lack necl-2 ex-
pression because of the loss of heterozy-
gosity of one Necl-2 allele and the 
epigenetic inactivation of the second 
  allele (23). This lack of necl-2 reduces 
epithelial cell adhesion and promotes 
invasion, and also allows neoplastic cells 
to avoid detection by NK cells and T 
cells. Some tumors, however, express high 
levels of other members of the nectin/
necl family, such as necl-5, which also 
promotes motility and the metastatic 
potential of tumor cells (29). Why 
  lymphocytes expressing activating re-
ceptors for Necl-5 do not eliminate 
these tumor cells is unclear. In vivo, tu-
mors may secrete or shed soluble forms 
of necl-5 that act as decoys to prevent 
the recognition of necl-5 on their 
  surface. Alternatively, lymphocytes may 
express yet unknown inhibitory recep-
tors for necl-5.
Finally, exposure of nectins and necls 
may also play a role in tissue   remodeling 
during injuries and chronic wounds. For 
instance, recognition of nectin and necls 
may serve as a mechanism for the  removal 
of damaged cells by NK or T cells, 
thereby restoring normal tissue architec-
ture. Alternatively, if nectins and necls 
on epithelial cells are continuously ac-
cessible to NK cells and T cells, these 
epithelial cells may be targeted for kill-
ing, hindering the healing process.
Concluding remarks
The characterization of KLRG1 as a 
cadherin receptor, and previous studies 
showing NK and T cell recognition of 
CEACAM, nectins, and necls, high-
lights the capacity of the immune sys-
tem to detect molecules involved in 
tissue organization. The challenge now 
is to understand how all these potential 
interactions are integrated in physiologi-
cal settings and how the resulting signals 
modulate the immune response against 
tumors that disrupt tissue organization.
The impact of each interaction is most 
likely determined by several factors. The 
distribution of lymphocytic   receptors on 
diff   erent cell subsets and their expres-
sion under steady-state, infl  ammatory, 
and neoplastic conditions are crucial is-
sues that need to be investigated further. 
Another important factor is the acces-
sibility of the epithelial cell   ligands for 
their lymphocytic receptors. Such avail-
ability might be inversely proportional to 
homotypic and heterotypic   interactions 
mediated by cadherins, CEACAMs, nec-
tins, and necls. It is conceivable that 
a loss of cell polarity and tissue architec-
ture may favor lymphocyte–epithelial 
cell interactions over epithelial–epithe-
lial interactions (Fig. 1). The   hierarchy 
of these cell–cell contacts will also 
depend on binding affi   nities and binding
sites. It has been shown, for   example, that 264  EMERGING INTERACTIONS BETWEEN CYTOLYTIC LYMPHOCYTES AND EPITHELIAL CELLS | Colonna
the αEβ7-binding site on E-cadherin does 
not overlap the site   involved in homo-
philic E-cadherin interactions (19). Thus, 
E-cadherin–E-cadherin binding does 
not preclude αEβ7 binding to E-cadherin 
and thus both signals could be transduced 
simultaneously. Structural studies are 
now necessary to defi  ne the molecular 
ba  sis of KLRG1–cadherin binding. Stud-
ies investigating the unknown aspects 
of these receptor–ligand interactions will 
not only contribute to our understanding 
of the maintenance of tissue organization 
and the control of tumor progression, but 
may also provide novel targets for in-
terven    tion in tumor therapy.
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